TrialBreast cancer (Tokyo, Japan)2017

Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative study.

Junichi Kurebayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.